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cost-effective over rivaroxaban. ConClusions: In patients treated for acute pul-
monary embolism, dabigatran is a cost-effective alternative compared with both 
warfarin and rivaroxaban.
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objeCtives: To evaluate cost-effectiveness of the novel oral anticoagulant apixa-
ban compared to warfarin and aspirin in patients with NVAF from the Russian 
Federation national health care system perspective. Methods: Cost-effectiveness 
analysis was based on a Markov model that allowed estimation of the incremen-
tal cost-effectiveness ratio (ICER) for apixaban compared to warfarin and aspirin 
over lifetime horizon in vitamin K antagonists (VKA) suitable and VKA unsuitable 
patients with NVAF, respectively. The model enclosed cardiovascular event rates 
derived from the randomized clinical trials: ARISTOTLE and AVERROES. The fol-
lowing cardiovascular events were considered: ischemic and hemorrhagic stroke, 
intracranial hemorrhage, systemic embolism, other major bleeds, clinically rele-
vant non-major bleeds, myocardial infarction and cardiovascular hospitalizations. 
Characteristics of the baseline patients’ cohort including quality of INR control 
corresponded to the local population. Direct medical costs were determined based 
on the rates of the compulsory national medical insurance system. The price of 
the antithrombotic drugs was taken as a weighted average tender price in 2013. 
Cost-effectiveness threshold was set at 1,4 million rubles per quality-adjusted 
life year (QALY) gained and corresponded to the three times GDP per capita in 
the Russian Federation in 2013. One-way sensitivity analyses were undertaken to 
examine the effects of model drivers. Results: In the base case analysis it was 
demonstrated that apixaban compared to warfarin and aspirin provided additional 
0.187 and 0.214 QALYs, respectively. With that estimated ICER for apixaban com-
pared to warfarin and aspirin was 603.92 and 473.02 thousands rubles per QALY 
gained, respectively. Sensitivity analysis indicated that results were robust over 
explored range of inputs. ConClusions: According to the results of the modeling 
study apixaban may be considered as a cost-effective alternative to warfarin in 
VKA suitable patients and as a cost-effective alternative to aspirin in VKA unsuit-
able patients for NVAF treatment from the Russian Federation national health care 
system perspective.
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objeCtives: This economic evaluation aimed to assess the cost-effectiveness of 
dabigatran compared with warfarin, in the treatment and secondary prevention 
of acute venous thromboembolism (VTE) comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), in the UK health care setting, based on safety 
and efficacy data collected during pivotal phase III trials. Methods: A life-time 
Markov state-transition cohort model was developed around the two primary 
composite endpoints in the pivotal trials: recurrent VTE and VTE-related death 
(rVTE), and major or clinically relevant bleeding (MCRB). Intervention-specific 
probabilities of events within the composite endpoint rVTE (recurrent DVT; recur-
rent PE) and the composite endpoint MCRB (intracranial haemorrhage; other major 
bleeds; non-major bleeds) were sourced from the pivotal trials. Beyond the trials 
follow-up period, the probability of rVTE was sourced from the literature. Long-
term consequences of VTE were considered, namely chronic thromboembolic pul-
monary hypertension and post-thrombotic syndrome. The perspective on costs 
was that of the NHS and Public Social Services. Health outcomes were assessed 
in quality-adjusted life years (QALY). Utility values for health states and events 
were EQ-5D data collected within the clinical trials, and the published literature. 
Probabilistic sensitivity analyses (PSA) were undertaken. Results: In patients 
with index DVT, the estimated incremental cost-effectiveness ratio (ICER) of treat-
ment with dabigatran compared with warfarin was £614 per QALY gained; in 
patients with index PE, the ICER was £1,285/QALY; in the pooled DVT/PE group, the 
ICER was £862/QALY. In the treatment followed by secondary prevention analysis, 
ICER was £8,319/QALY. PSA suggested that the probability of dabigatran being 
cost-effective at a threshold of £30,000/QALY was 90%, 81% and 94% in acute 
treatment and 96% in secondary prevention respectively. ConClusions: In a 
UK setting, dabigatran appears to be a cost-effective option for treatment and 
secondary prevention of VTE in patients with acute DVT and acute PE compared 
with warfarin.
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objeCtives: The aim of the study was to compare the cost-utility of the two single-
pill triple combination antihypertensive therapies available in the Greek market 
for patients with moderate to severe hypertension; the valsartan (V) against the 
olmesartan (O) combination with amlodipine (A) and hydrochlorothiazide (H).  
Methods: A Markov model with eight health states was constructed. The short-
cost-effectiveness of surgery, endodermal ablation (ETA), ultrasound guided foam 
sclerotherapy (UGFS) and compression stockings (CS). The analysis was based on a 
Markov decision model, which was developed in consultation with members of the 
NICE guideline development group (GDG). The model had a five year time horizon, 
and took the perspective of the UK National Health Service. Clinical inputs were 
based on a network meta-analysis (NMA), informed by a systematic review of the 
clinical literature. Outcomes were expressed as costs and quality adjusted life years 
(QALYs). Results: All interventional treatments were found to be cost-effective 
compared to CS at a cost- effectiveness threshold of £20,000 per QALY gained. ETA 
was found to be the most cost-effective strategy overall, with an incremental cost-
effectiveness ratio of £3,161 per QALY gained compared to UGFS. Surgery and CS 
were dominated by ETA. ConClusions: Interventional treatment for VV is cost-
effective in the UK NHS. Specifically, based on current data, ETA is the most cost-
effective treatment in people for whom it is suitable. The results of this research 
were used to inform recommendations within the NICE guideline on VV. Funding: 
This work was undertaken by the National Clinical Guideline Centre, which received 
funding from the National Institute for Health and Clinical Excellence (NICE). The 
views expressed in this publication are those of the authors and not necessarily 
of the institute.
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objeCtives: Venous thromboembolism (VTE) including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) is a common cardiovascular disorder. Acute 
VTE has been traditionally managed with short course parenteral anticoagulation 
followed by 3-6 months of a vitamin-K antagonist. Novel oral anticoagulants do 
not require routine coagulation monitoring and dose adjustment, thus potentially 
providing an alternative treatment option. The cost-effectiveness of dabigatran vs. 
rivaroxaban over a 6 months treatment course in the UK health care setting was 
evaluated in this research. Methods: A life-time Markov model was developed, 
encompassing recurrent VTE events and VTE-related deaths, and the most com-
mon adverse events during anticoagulation therapy: major or clinically relevant 
bleeds (MCRB). The model was populated with data from pooled RE-COVER and 
RE-COVER II dabigatran trials and the 6 months treatment duration subgroup of 
the rivaroxaban EINSTEIN-DVT and EINSTEIN-PE trials. Long-term consequences 
of VTE were considered. Costs were analysed from the NHS and Public Social 
Services perspectives. Health outcomes were assessed in quality-adjusted life 
years (QALY). Utility values for modelled health states were EQ-5D data from 
RE-COVER studies, and published data. Probabilistic sensitivity analyses (PSA) 
were undertaken. Results: In patients with index PE, 6 months treatment with 
dabigatran dominated treatment with rivaroxaban projecting less recurrent VTE 
and less MCRB at lower costs. Dabigatran was likely to remain cost-effective in 70% 
of cases at a threshold used in the UK of £30,000/QALY gained. Dabigatran contin-
ued to dominate treatment with rivaroxaban in patients with index DVT, project-
ing less non-fatal PE, less intra-cranial haemorrhages and less clinically relevant 
bleeds, but more recurrent DVT, with 68% likelihood of remaining cost-effective. 
In the pooled DVT/PE group, dabigatran dominated treatment with rivaroxaban 
and was 62% likely to remain cost-effective. ConClusions: Dabigatran is less 
costly and more effective than rivaroxaban when administered for 6 months after 
index PE, index DVT or both.
PCV96
thE Cost-EffECtiVEnEss of dAbigAtrAn EtExilAtE ComPArEd With 
WArfArin And riVAroxAbAn in thE trEAtmEnt of ACutE PulmonAry 
Embolism in thE uk
Jugrin A.V.1, Ustyugova A.V.2, Urbich M.3, Lamotte M.1, Sunderland T.J.4
1IMS Health HEOR, Vilvoorde, Belgium, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, 
Germany, 3Boehringer Ingelheim Ltd, Bracknell, UK, 4Boehringer Ingelheim, Berkshire, UK
objeCtives: This economic evaluation aimed to assess the cost-effectiveness 
of dabigatran etexilate for six months of treatment for acute pulmonary embo-
lism (PE) compared with warfarin and rivaroxaban in the UK health care set-
ting. Methods: A Markov state-transition cohort model was used to project the 
lifetime recurrence of PE and occurrence of deep vein thrombosis (DVT) in patients 
with initial acute PE. The incidence of recurrent venous thromboembolism (rVTE) 
was based on the relevant study endpoints of RE-COVER and RE-COVER II trials 
comparing dabigatran with warfarin, and the EINSTEIN-PE study for rivaroxaban. 
Intervention-specific probabilities of events within the composite efficacy end-
point and within the composite safety endpoint of major or clinically relevant 
bleeding (MCRB) were sourced from the very same randomised trials. Beyond 
the data from clinical studies, the probability of rVTE was sourced from the 
published literature. Long-term consequences of VTE were considered, namely 
chronic thromboembolic-induced pulmonary hypertension and post-thrombotic 
syndrome. The perspective on costs was that of the NHS and Public Social Services. 
Health outcomes were assessed in quality-adjusted life years (QALY). Utility val-
ues relevant to events and health staes were EQ-5D data from RE-COVER studies, 
and published literature. Probabilistic sensitivity analyses (PSA) were under-
taken. Results: Compared with warfarin, dabigatran projected similar number 
of rVTE, but was associated with less MCRB. The expected lifetime incremental 
cost-effectiveness ratios (ICERs) were £2,004/life years (LYs) and £1,285/QALYs. PSA 
showed 84% likelihood for dabigatran to remain cost-effective given a willingness-
to-pay of £30,000/QALY. When compared with rivaroxaban, treatment with dabi-
gatran was projected dominant,. Dabigatran projected less rVTE, less intracranial 
haemorrhages and clinical relevant non-major bleeds, but was associated with a 
higher risk of major bleeds. PSA showed 66% likelihood for dabigatran to remain 
